Oncology

Metastatic Pancreatic Cancer

Advertisment

Routine Laboratory Parameters Predict Patients at Risk for Early Mortality in Pancreatic Cancer

clinical study insights by Alok Khorana, MD

Overview

Clinical Study Abstract:
Survival after surgical resection for pancreatic cancer remains poor. A subgroup of patients die early (<6 months), and understanding factors associated with early mortality may help to identify high-risk patients. The Khorana score has been shown to be associated with early mortality for patients with solid tumors. In the current study, the authors evaluated the role of this score and other prognostic variables in this setting.

  • Methods: The current study was a cohort study of patients who underwent surgical resection for pancreatic cancer from January 2006 through June 2013. Baseline (diagnosis ±30 days) parameters were used to define patients as high risk (Khorana score ≥3). Statistically significant univariable associations and a priori prognostic variables were tested in multivariable models; adjusted hazard ratios (HR) were calculated.
  • Results: The study population comprised 334 patients. The median age was 67 years, 50% of the study population was female, and 86% of the patients were white. The pancreatic head was the primary tumor site for 73% of patients; 67% of tumors were T3 and 63% were N1. The median Khorana score was 2; 152 patients (47%) were determined to be high risk. Adjunctive treatment included chemotherapy (70%) and radiotherapy (40%). The postoperative (30-day) mortality rate was 0.9%. The 6-month mortality rate for the entire cohort was 9.4%, with significantly higher rates observed for high-risk patients (13.4% vs 5.6%; P=0.02). On multivariable analyses (examining a total of 326 patients), the Khorana score (HR for high risk, 2.31; P =0.039) and elevated blood urea nitrogen (HR, 4.34; P<0.001) were associated with early mortality.
  • Conclusions: Patients at high risk of early mortality after surgical resection of pancreatic adenocarcinoma can be identified using simple baseline clinical and laboratory parameters. Future studies should address preoperative interventions in these patients at high risk of early mortality.

Reference:
Sohal DP, Shrotriya S, Glass KT, Pelley RJ, McNamara MJ, Estfan B, Shapiro M, Wey J, Chalikonda S, Morris-Stiff G, Walsh RM, Khorana AA. Predicting early mortality in resectable pancreatic adenocarcinoma: a cohort study. Cancer. 2015;121(11):1779-1784.

Expert Commentary

Alok Khorana, MD

Professor of Medicine
Director, Gastrointestinal Malignancies Program
Cleveland Clinic
Cleveland, OH

Pancreatic cancer remains a highly lethal disease. It is climbing in the ranks of leading causes of cancer-related deaths, and it is expected to become the second-leading cause of cancer-related deaths very shortly, perhaps even sooner than anticipated. I was involved in a cohort study with Sohal et al to assess risk factors associated with early mortality in an effort to identify high-risk patients. Our results demonstrated that routine parameters that are available on almost every single patient being treated for pancreatic cancer may be able to assist in identifying those patients who are at higher risk of early mortality. Studies such as this one will help improve treatment in these patients, especially with the recent growing trend toward more aggressive preoperative therapies for resectable and borderline resectable pancreatic cancer.

“Our results demonstrated that routine parameters that are available on almost every single patient being treated for pancreatic cancer may be able to assist in identifying those patients who are at higher risk of early mortality.”

Alok Khorana, MD

Alok Khorana, MD

Professor of Medicine
Director, Gastrointestinal Malignancies Program
Cleveland Clinic
Cleveland, OH

Advertisment